Free Trial
OTCMKTS:GTHP

Guided Therapeutics Q2 2025 Earnings Results & Report

Guided Therapeutics logo
$0.18 -0.02 (-10.00%)
As of 10/9/2026 01:51 PM Eastern

Guided Therapeutics reported Q2 2025 earnings on August 14, 2025. The company reported EPS of -$0.01, while revenue was $0.12 million.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
During Market Hours

Guided Therapeutics EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Guided Therapeutics Revenue Results

Actual Revenue
$0.12 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Guided Therapeutics Q2 2025 Earnings FAQ

Guided Therapeutics (OTCMKTS:GTHP) reported earnings of -$0.01 per share for Q2 2025. The report was announced on Thursday, August 14, 2025.

Guided Therapeutics reported revenue of $0.12 million for Q2 2025.

Guided Therapeutics Earnings Headlines

Why I went to Mount Rushmore
A small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technology. This could be one of the biggest gold finds since the 1870s, yet the stock still trades around 6 dollars. BlackRock and Vanguard have been quietly loading up on shares while most investors have missed the story. The same technology is unlocking hidden resource wealth across America, driving stocks up 227 percent, 378 percent, and even 773 percent.tc pixel
See More Guided Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Guided Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Guided Therapeutics and other key companies, straight to your email.

About Guided Therapeutics

Guided Therapeutics (OTCMKTS:GTHP), Inc. is a medical technology company focused on developing diagnostic products for women’s health. The company’s primary focus has been the detection of cervical disease and cancer using minimally invasive or non-invasive technologies.

Its lead product, LuViva Advanced Cervical Scan, is designed to evaluate cervical tissue using optical spectroscopy. The system analyzes changes in tissue characteristics that may be associated with precancerous or cancerous conditions and is intended to help clinicians identify patients who may require additional evaluation, including biopsy.

Guided Therapeutics has pursued regulatory and commercial opportunities for its cervical disease detection technology in the United States and international markets. The company is headquartered in Georgia and has historically focused its operations on developing, validating and commercializing diagnostic devices rather than providing direct medical care.

View Guided Therapeutics Profile